pandemic Carrie. COVID-XX review as Thanks our and well your and and possible. results. for I you the call you as our joining afternoon Good thank to hope XXXX healthy first-quarter families managing are
want flexibility thanking to several Before we and past by go the amazing details into over months. start the I employees quarter, drive for the our of their dedication,
to customers community relentlessly the in members. to working by best but develop work been the to truly cures a and out virus. just COVID-XX are world, I take each around and the for our acknowledge moment our has who done intense the of research period, team being understand a collective the it This very also want brought
focused scientific seen have pandemic we not with like a never in global our also intensity single on we the a so have community goal. lifetime, While much seen this
moved quickly to working soon started As the instruments reagents pandemic on as place customers to the world, COVID-XX research. and we provide spreading around our
these Many instruments labs. put require in special biosafety three to of level customers accommodations
fight products multiple and Fundamentally, allow and discoveries biology Our virus And resolution they researchers to and pandemic. vaccines. accelerate make enable they help at underlying the in the used because see the disease of to the very ways to against of biology develop to our are high being understand therapies and the scale. customers to that,
clinicians the already of the which in patients could understand biology the neutralizing of using be to There and for extensive using for of for search by Profiling antibodies There our and customers have and around reference and tissues XXx cell have customers A where. in world when virus, recovered products. prophylaxis infection analysis COVID-XX solution which potentially scientists research. full using suite organs tissues Large-scale to been infected research from our and single been treatment. to the get our dozens of lung establish other cells have number allowed the now used is Immune ongoing
system's the of intensely are vaccine. to the infection Many understanding our customers immune on focused or response
clones Here, for stages our view with what comprehensive is particularly has detailed a different powerful immune and different the infection. Immune because of it Profiling provides solution cells, happening genes been and during
the breathtaking. has overreactions. neutralize published by inflammatory dangerous been the infection to are those out and teasing been the have precise pace and of that virus as as customers activated well unpublished, cells discovery, Our receptors that The both produce
doing At could how effective can crisis how is solved. Technology everything effective ultimately understand the treatments an This research to this discovery is biomedical this achieve helping vaccine we be of effects will virus be when keep will what has help the the on patients, and kind community be goal. we developed. different scientists and scientific would XXx,
Turning our to business. now
call reviewing first from COVID-XX. detail the commercial including quarter impact today's on by during start the execution our I'll
I and what priorities how in through new the I financials at Next, from Then will turn recovery, the like more our pandemic. Justin the call COVID-XX. I as key COVID-XX. will normal our both near and the term look finally, post navigate industry, will discuss detailed broader business we're And the for the we impact look the a to over our will XXx through thinking walk for and about
concluding I remarks, will Q&A. will and then some join us Brad return for for
the Chromium strong XX% revenues with The $XX.X grew Visium quarter year see biopharma relative for sales the to We Our especially to period. pleased the started first in products. a prior for to both and demand compared off notable prior-year year. to million were as increase
we over late capabilities introduced excited February, workshop and launch at outlined months road and we these a capabilities our AGBT the our Conference, years. to map hosted of we're number new strongly customers. the resonating for In Visium And with new been The we a where Chromium coming platforms. has both
the made Cloud for expression, a of solutions and targeted the help democratize to side, single including several On announcements new for of and combined assays the Chromium epigenetics gene XXx measurement cell we introduction analysis. product the
is upcoming AGBT, the to through in We tests. its our compatibility, saw product a ago, the sample IHC we look for has especially months forward while the which have feature enthusiasm throughout We capabilities at as to adoption platform we seen launched already previewed Relative the Chromium, solutions its these just measurements few And our platform barcoding great protein around technology and enablement first FFPE year. still world. releasing Visium Visium extensive infancy. we included of
being cases. use call after by they well have last labs. to doubled labs, Visium number used initial told many than new Across you XXX from XXX. That the down data experiments been was excitement we our started these more seeing has by spanning that than mid-February, customers On more their over encouraged as earnings in amazing we our different
month the we of quarter, particularly from majority the did of see for during March. impact substantial strong was business our a While the COVID-XX,
activity when of the March, across early approximately By in started see attributed responded that globally, as to our customers significant China as quarter, only pandemic. January labs have in saw cases suspended virtually orders. confirmed the our notable slowdown sign in we COVID-XX the XX% In to the we spread in began as emerging research. with was estimate across end country the institutions The exception pandemic. we a response customer base began a reduction first to was stay-at-home of to shut down The COVID-XX-related operations to compliance
closures the will our continue full use These -- reopen solution regain they and business seen These are impacted to has labs making profiling able has been strong demand. have of until and all impact have our been surprisingly, not lab products, new but capacity. of to particularly
reemergence them seen back have And to As of remain full labs time to recent even most up capacity. are open, labs some weeks. of but in activity closed, get take customer today, for it once we some will
While biology hard master the of knowledge recovery striking of post-COVID in the a world. precise This the pandemic consequences shape way the in current the to of to showing very understand is there's predict, of the limitations. limitations is and about little those our frightening biology need doubt the particularly
business. the future, we confidence to look have our we as in strong So very
be and forward, for our and XXx will These greater The we to crucial even industries and will for expect investments biology investments understanding drive biomedicine plan have governments. needs build technologies. products Going of in at human advancing new, built accelerating new across sustained we health.
infectious the several urgency, past and papers our now make to products very increasing And do. customers small discoveries is they disease. expect. truly including how with areas many have been to we using impact years, of breakthroughs relative our using we published so by health the across XXX to available is have our amazing been The our have Over disease, XX products to much the scientific over many still powered in researchers fundamental months of human It have more products number eventual researchers.
just so the this is And beginning.
platforms the more are have We stages are, anything, than early front of of in development their see product us product opportunities if potential. been. robust relative the ever to in development that they Our
by analysis It of and XXX patents single multi-omics. is engine now epigenomics, competitive supported and foundational is Our pillar including a in innovation analysis, cell patents core spatial advantage. over our applications,
Our aggressively health. accelerate continue to human advances future discovery and priority to in platforms R&D and products new in to develop invest is to
sciences, Virtualization precipitated ways. to that focus will even to biomedicine that addition increased the other subsides. be likely be shift pandemic the social is on life expect the we distancing post-COVID and In by in world stay us different after permanent a with will
things. doing future. be of more the not and much will the work in new them are of to rare ways and more older Travel, going effective. efficient likely discovering patterns in-person and adopting back be People interacting more can now digital to likely of ways in-person Many are visits conferences
our our We a new providing we capabilities the invaluable our into support they we conditions have in invested visits. under maximize in substantially platform customers effectively been allowed and especially fortunate as where forms that several are of also proven and promote customers and years, with marketplace. products to in-person the Webinars past success teams. us absence digital field customer of in interactions outreach digital can launch current help other the have These have to
digital the will that these particularly as investments be and now that expect in will foundation the capabilities We valuable future. serve
ever being have being This more reasoning that adaptable a the fast more we XXx, lot first moving moving of of than nimble always and on it's ourselves from suggests will At it changes is principles. causing in more has, pride and general matter the it world. effect the pandemic and throughout now matters A that future. fast,
and keep them. investing will qualities future culture these that to expect at We to processes a in in intend premium the our be promote and
business as And priorities now we near-term to our the through our pandemic. navigate turning
of serve the efforts first, third, have research continuity operations to COVID-XX; to customers prioritize of development. them on health around second, to to support keep our our X to investments all and their employees; critical We to organized safety the focused on ensure and principles: importantly, protect and
and U.S., XXx business began designated pandemic. measures our essential took protection As the necessary we to COVID-XX early during cases the rise and ensure as the employees. in of operations continue action an to was to well-being implemented
back home. for a of functions and to other transitioned weeks employees more deliberate distancing majority to started a critical stringent is into to work keep frequently R&D while from safe vast manner. one under of our and operating the social group ago, safety, ways to team's ensure bringing work test basis. Several a measures. that additional retained everyone and We most a effective to careful protective the operations protocols on-site on we of with in protections our We the Initially, core SARS-CoV-X labs believe our environment of employees ensure going recurring
mind, employees at testing on-site to have SARS-CoV-X in With recurring provide our all to novel be set person. for headquarters in program need we that up a that
to suppliers chain remains our that with We are regularly also ensure our communicating intact. supply
We recovery a we hand supply have not taken material demand and experienced to range issues have to any scenarios. inventory meet of on steps yet adequate across ensure have customer
operating service teams to customers customer and and around the world are remotely assist remain our Our partners. available
customer mentioned earlier, digital our to I As teams approaches interactions. quickly commercial switched for
We to been content and afar. have online educate, Sales have have customers of to organized our attendance. potential our virtual running from record We've series extensive train webinar teams and made seeing been consistently use help educate customers meetings.
In conferences be appears than meetings. of fact, the effectiveness for higher virtual substantially to in-person
deliberately. our and about environment tremendous continuing is strong Supported business macro we us. of balance our the wealth uncertain, importantly, R&D sheet, and in remain are conviction of we strong scale a near-term infrastructure. the invest the ahead long to thoughtfully and likely run we opportunities by are continuing operational have While Most to to
to current we diligence diligent that This toward we prioritization. executing to especially always development effectively done aspect environment for XXx, academic for technologies At goals. long-term our medicines of very for at technologies and are important is we're XXx, build out measure make ensure focusing projects, available everyone, As to key or to being around the new we with biology treating of have patients. whether set these in every investments research,
necessary the able how biological relevance given be to right every because vision with we the is the that end, you any analyte should sample, Our of comfort resolution measure understanding. that's will achieve of all in
will that, now to With we cures. Justin for how at will arrive details the more on call That's turn our over I financials.
